Chief Pfizer: Anti - Vaccination CO VID can become annual

Albert Bourla said he thought this would be necessary to maintain a very high defence “”.

Pfizer's chief executive was talking about the BBC prior to the Omitron version show, first identified in South Africa and also prior to the announcement that the Great Britain government had signed contracts to buy 54 million additional Pfizer doses - B NTech and 60 million dosza Modernna for 2022 and 2023.

Bourla said Pfizer had already made updated vaccines in response to Beta variants, originally identified in South Africa and Delta, identified for the first time in India, but that they were not necessary.

The company is now working on an updated vaccine in response to the Omitron variant that could be ready in 100 days.

He said vaccines had helped save millions of lives during the pandemic and without them “the basic infrastructure of our society would be threatened”.

By the end of the year, Pfizer expects to have supplied three billion doses of its written ribonucleic acid vaccine ( m RNA, with four billion planned for next year.

There had been a global race to protect protected people, Dr. Bourla said, but in 2022, the countries would have “ac doza as much as they need”.

Some global health charities view the money Pfizer, BioNTech, and Moderna are extracting from the pandemic as immoral.

Pfizer will generate at least $35 billion in sales of vaccines against Covid this year and has seen the increase in its share price.

But while most people in the world have now had at least one vaccine CO VID, in parts of Africa, is less than one person in 20.

Bourla did not apologize for the profit, saying the “end is that millions of lives were saved”.

We have saved the global economy trillions of dollars. It's a strong incentive for innovation for future pandemic. But people will see that if they open the game to bring about something that saves life and saves money, there is also a financial reward,” he said.

He denied the benefit by saying that the mouth was “the process of a food meal” for the richest countries, but was sold for no profit to low incomes, but the accepted countries as Great Britain had made early orders and the availability was initially limited.

Pfizer has also developed an antiviral pill, Paxlovov, which in evidence reduced admissions to hospitals and deaths to nearly 90%. It must soon be approved in the US, and the British government has agreed to buy enough for 250,000 patients.